South Korean biotechnology mergers and acquisitions are shifting away from single candidate drugs toward platform technologies and management buyouts, according to Deloitte Anjin.
Pyun Je-sung, a senior executive director in Deloitte Anjin’s corporate finance division, outlined the market transition. Deal-making previously focused on the technical potential of individual drug pipelines, but future transactions will target companies with established platform technologies and broader business capabilities.
Pyun joined Deloitte Anjin in 2018 after working at Dong-A Pharm, Dong-A ST, SK Chemicals, and IQVIA. His advisory work includes IMM PE’s sale of Genewon Science, Woojung Bio’s sale, Glenwood PE’s post-merger integration of InverTross—formerly LG Chem’s in-vitro diagnostics business—and Taekwang Industrial and UAMCO’s integration of Dongsung Pharm.
Investment strategies for domestic biotechnology and healthcare firms changed around the COVID-19 pandemic, Pyun said. The dominant model before the pandemic involved licensing early-stage candidate substances from overseas, developing them just before Phase 1 clinical trials, and then out-licensing them to global pharmaceutical companies. This approach is known as the No Research, Development Only model.
Market focus shifted after the pandemic toward platform companies capable of replicating success across multiple products. “Because the drugs that proven technology can be applied to are endless, royalties naturally expand,” Pyun said, citing Alteogen as a prime example of a platform company with technology that converts intravenous drugs into subcutaneous formulations.
This evolution is pushing domestic transactions toward corporate buyouts. While large pharmaceutical companies in the United States and Europe frequently acquire entire biotech firms, similar transactions have remained rare in South Korea.
“You need core technology for acquisition demand to arise, because it is better to acquire the enterprise than just borrow proven technology,” Pyun said.
Contract development and manufacturing organizations will likely see deals split into two distinct paths, according to Pyun.
Large enterprises like Samsung Biologics will continue pursuing cross-border mergers and acquisitions to secure global production bases, diversify clients, and strengthen technical capabilities. Domestic pharmaceutical companies and small-to-midsize contract manufacturers will concentrate on domestic acquisition opportunities.
Aesthetics and medical device transactions, which remained active over the past one to two years, continue to offer attractive growth and profitability. However, the market faces pressure in absorbing high corporate valuations, Pyun said.